Age Related Macular Degeneration
Conditions
Keywords
Anti vascular endothelial growth factor, retinal vessels
Brief summary
Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE). Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye
Interventions
Sponsors
University of Malaya
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
• Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease
Exclusion criteria
* History of previous systemic or ocular Anti-VEGF therapy * History of previous intravitreal injection with any drug * Intraocular pressure ≥ 22 * Glaucoma * History or presence of thromboembolic events * Un-controlled blood pressure * Blood donation during the previous 3 weeks * Relevant media opacity of the lens
Countries
Malaysia
Contacts
Primary ContactMohammadreza Peyman, MD
Backup ContactVisvaraja Subrayan, Prof
Outcome results
None listed